According to a press release issued by Perimeter Medical Imaging AI (TSXV:PINK; OTCQB:PYNKF), it closed the final tranche of a prospectus offering of units of the company, in which its CEO, Adrian Mendes, participated to the tune of $1 million.
Pursuant to the final tranche, the Company issued an aggregate of 7,416,667 units at a price of $0.30 per unit for aggregate gross proceeds of approximately $2.25 million. Inclusive of the closing of the initial tranche, the company issued an aggregate of 17,849,468 units, for aggregate gross proceeds of approximately $5.35 million. Perimeter said it does not expect to close any further tranches of the offering.
Each unit is comprised of one common share in the capital of Perimeter and one common share purchase warrant. Each Warrant entitles the holder to acquire an additional common share for a period of 60 months, at an exercise price of $0.35.
Perimeter disclosed that Mr. Mendes purchased a total of 3,333,334 units under the offering.
In the company’s quarterly report for the first quarter of 2025, Mr. Mendes said, “This has been a pivotal start of the year for Perimeter, marked by record revenue from sales of our current S-Series system, the presentation of positive pivotal trial results for our next-generation AI-enabled B-Series product at ASBrS, the world’s premier breast cancer surgical conference, and of course, the filing of the FDA PMA application for the upcoming B-Series. He added, “That positive momentum has continued into the current second quarter, as demonstrated by the achievement of several commercial milestones in April. We look forward to updating investors as we progress.”
